Electromed, Inc.

NYSE American ELMD

Electromed, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024

Electromed, Inc. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Electromed, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was 11.11%, a 52.40% change year over year.
Electromed, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was 7.29%, a -20.93% change year over year.
Electromed, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was 9.22%, a -38.15% change year over year.
Electromed, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was 14.91%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NYSE American: ELMD

Electromed, Inc.

CEO	Mr. James L. Cunniff
IPO Date	Aug. 13, 2010
Location	United States
Headquarters	500 Sixth Avenue NW
Employees	174
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Key trends

Past 5 years